E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002034 |
E.1.2 | Term | Anaemia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the efficacy of the combination of EPO and TDI of CosmoFer® to the combination of EPO and oral Fe for the correction of anaemia and re-plenishment of Fe stores in patients with haematological malignancies by comparing the mean change in Hb g/dl levels from baseline to week eight. |
|
E.2.2 | Secondary objectives of the trial |
To compare the safety of the combination of EPO and TDI of CosmoFer® to the com-bination of EPO and standard oral Fe for: The correction of anaemia in patients with haematological malignancies. The correction of anaemia in patients with haemato-logical malignancies by comparing the mean change in Hb g/dl levels from baseline to week two and four. The correction of anaemia in patients with haemato-logical malignancies by comparing number of erythroid responders (defined as an in-crease in Hb levels by at least 2 g/dL compared to baseline) after two, four, and eight weeks of treatment in the two treatment arms. The correction of anaemia in patients with haemato-logical malignancies by comparing other parameters of haemopoiesis (Hct, RTLCs, se-rum Fe, TSAT, serum Ferritin, MCH, MCHC, and MCV) after two, four and eight weeks of treatment in the two treatment arms.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with newly diagnosed CLL, lymphoma (both Hodgkin’s and Non Hodgkin’s lymphoma) or MDS (RA, RAS, RAEB, and CMML) with a need for Fe due to anaemia and ESA treatment Age ≥ 18 years at screening Hb ≤ 11 g/dL Serum Ferritin < 800 µgram/l TSAT < 30 % MCV < 85 ECOG PS 0-2 Life expectancy beyond 12 months Willingness to participate after written informed consent
|
|
E.4 | Principal exclusion criteria |
Non-Fe deficiency anaemia (Vitamin B12 deficiency, folic acid deficiency, gastrointestinal bleeding, or hemolysis) Fe overload or disturbances in utilisation of Fe (e.g. haemochromatosis and haemosiderosis) Previous hypersensitivity to Fe Dextran or Fe mono- or disaccharide complexes Patients with a history of asthma, eczema, or other atopic allergies Decompensated liver cirrhosis and hepatitis (ALAT > 3 times normal) Acute or chronic infections (evaluated by clinical judgement derived by WBC and CRP if deemed necessary by investigator) Rheumatoid arthritis with symptoms or signs of active inflammation Pregnancy or nursing. To avoid pregnancy, women have to be postmenopausal, surgically sterile, sexually inactive or practice reliable contraception Planned elective surgery during the study where significant blood loss is expected Participation in any other clinical trial within three months prior to screening Uncontrolled hypertension (> 140/90 mmHg) despite optimal therapy Known epilepsy Renal dysfunction (serum creatinine > 2.0 mg/dl) Prior RBC transfusion within the past two weeks Prior Fe dextran treatment within the past four weeks Prior EPO treatment within the past four weeks
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the mean change of Hb (g/dl) from baseline to EOS (week eight) or to the time of early withdrawal. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |